NCT03828292View on ClinicalTrials.gov

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 14, 2019

Primary Completion Date

April 6, 2023

Study Completion Date

September 5, 2024

Conditions
Multiple Myeloma
Interventions
DRUG

Belantamab mafodotin

Belantamab mafodotin will be administered as an intravenous infusion.

DRUG

Bortezomib

Bortezomib solution for injection will be administered subcutaneously.

DRUG

Dexamethasone

Dexamethasone tablets will be administered orally.

DRUG

Pomalidomide

Pomalidomide capsules will be administered orally.

Trial Locations (4)

150-8935

GSK Investigational Site, Shibuya-Ku

467-8602

GSK Investigational Site, Aichi

701-1192

GSK Investigational Site, Okayama

135-8550

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03828292 - An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments | Biotech Hunter | Biotech Hunter